Table 2.

Prediction of overall HCC at three separate time-points (546 controls vs. 357 cases).

	Time between sample collection and HCC diagnosis
	1–2 years (58 cases)	2–5 years (103 cases)	≥5 years (196 cases)
	Adjusted OR (95% CI)	Adjusted OR (95% CI)	Adjusted OR (95% CI)
M2BPGi level (index)
Negative (C.O.I < 1.00)	1.00	1.00	1.00
1.00 < C.O.I < 2.00	1.64 (0.69–3.91)	1.31 (0.65–2.63)	1.06 (0.64–1.74)
C.O.I ≥ 2.00	7.40 (2.40–22.78)c	6.46 (2.58–16.18)c	2.24 (0.97–5.15)
Age (in years)
30–39	1.00	1.00	1.00
40–49	0.87 (0.25–3.05)	0.50 (0.21–1.19)	0.46 (0.27–0.78)b
50–59	0.69 (0.20–2.39)	0.43 (0.18–1.02)	0.22 (0.13–0.39)c
≥ 60	1.45 (0.37–5.65)	0.69 (0.24–1.96)	0.05 (0.01–0.20)c
Sex
Female	1.00	1.00	1.00
Male	1.35 (0.50–3.63)	1.54 (0.66–3.58)	1.09 (0.64–1.86)
ALT (U/L)
<45	1.00	1.00	1.00
≥ 45	1.19 (0.40–3.54)	1.29 (0.58–2.88)	0.92 (0.42–2.01)
AST (U/L)
< 45	1.00	1.00	1.00
≥ 45	0.77 (0.21–2.83)	3.00 (1.26–7.15)a	1.20 (0.50–2.90)
AFP (ng/mL)
< 10	1.00	1.00	1.00
≥ 10	12.99 (4.82–35.03)c	5.40 (2.17–13.45)c	5.34 (2.43–11.70)c
HBV DNA level (copies/mL)
< 300	1.00	1.00	1.00
300–9999	0.23 (0.05–1.06)	1.12 (0.34–3.66)	1.34 (0.59–3.06)
10,000–99,999	0.27 (0.06–1.24)	0.96 (0.27–3.49)	1.05 (0.44–2.52)
100,000–999,999	0.22 (0.04–1.27)	2.32 (0.70–7.68)	1.07 (0.42–2.70)
≥ 1,000,000	0.41 (0.10–1.61)	1.22 (0.37–4.06)	1.03 (0.43–2.44)
HBsAg (IU/mL)
<100	1.00	1.00	1.00
100–999	2.85 (0.79–10.29)	2.16 (0.83–5.64)	3.19 (1.56–6.55)b
≥1,000	4.51 (1.21–16.77)a	2.77 (1.02–7.53)a	5.28 (2.55–10.93)c

^aIndicates significance at the P < 0.05 level (two-tailed test).

^bIndicates significance at the P < 0.01 level (two-tailed test).

^cIndicates significance at the P < 0.001 level (two-tailed test).